Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.96 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL1330152 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL951660 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL1331768 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL4378230 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL9300885 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL69781 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL118455 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL677128 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL28017793 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL3004014 | 0.96 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214984-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-03 | — | — | US | claimed |
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | claimed |
| CN-119390599-A | Acetyl L-carnitine hydrochloride derivative and preparation method and application thereof | 诚达药业股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-116898921-B | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation | 江西新世纪民星动物保健品有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117185945-A | Preparation method of acetyl L-carnitine hydrochloride | 湖北楚维药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116898921-A | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation | 江西新世纪民星动物保健品有限公司 | 2023-10-20 | — | — | CN | claimed |
| US-20230271952-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-31 | — | — | US | claimed |
| US-20230181475-A1 | COMPOSITION COMPRISING METHYLFOLATE | ALFASIGMA S.P.A. (IT) | 2023-06-15 | — | — | US | claimed |
| WO-2023084531-A1 | A SYNERGISTIC COMPOSITION FOR ACTIVATING INTRACELLULAR SECONDARY MESSENGER(CAMP) PATHWAY | Celagenex Research (India) Pvt. Ltd. (IN) | 2023-05-19 | — | — | WO | claimed |
| CN-115605188-A | Compositions comprising methylfolic acid | 阿尔法西格玛有限公司（IT） | 2023-01-13 | — | — | CN | claimed |
| WO-2001058850-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| CN-1284871-A | Compositions and methods for increasing concentration and motility of human sperm | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2001-02-21 | — | — | CN | claimed |
| WO-2000057873-A2 | GRANULATE WITH HIGH CONTENT OF L-CARNITINE OR AN ALKANOYL L-CARNITINE | BIOSINT S.P.A. (IT) | 2000-10-05 | — | — | WO | claimed |
| EP-1039894-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE CONCENTRATION AND/OR MOTILITY OF SPERMATOZOA IN HUMANS | Sigma-Tau Healthscience S.p.A. (IT) | 2000-10-04 | — | — | EP | claimed |
| US-6090848-A | SYNERGISTIC MIXTURE OF CARNITINE AND ACETYLCARNITINE | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2000-07-18 | — | — | US | claimed |
| EP-1001760-A1 | COMPOSITION FOR CONTROLLING MOOD DISORDERS IN HEALTHY INDIVIDUALS | Sigma-Tau Healthscience S.p.A. (IT) | 2000-05-24 | — | — | EP | claimed |
| US-6066664-A | ADMINISTERING 5-HYDROXYTRYPTOPHAN AND AN ALKANOYL L-CARNITINE WHERE THE ALKANOYL HAS 2-6 CARBON ATOMS, OR SALT THEREOF | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-05-23 | — | — | US | claimed |
| WO-1999027925-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE CONCENTRATION AND/OR MOTILITY OF SPERMATOZOA IN HUMANS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-06-10 | — | — | WO | claimed |
| WO-1998057629-A1 | COMPOSITION FOR CONTROLLING MOOD DISORDERS IN HEALTHY INDIVIDUALS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1998-12-23 | — | — | WO | claimed |
| WO-1998055117-A1 | METHOD FOR DECREASING THE APPETITE IN BULIMIC, OVERWEIGHT INDIVIDUALS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-12-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214984-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM5B, KDM5D | HRH1 1975/4885CHRM2 3507/4885CHRM4 3399/4885 |
| US-20230271952-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM5B, KDM5D | HRH1 1975/4885CHRM2 3507/4885CHRM4 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.